| Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -. | |
| | |
MedLine Citation:
|
PMID: 20519875 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Post-prandial hyperglycemia, hyperlipidemia, and endothelial dysfunction play an important role in the pathogenesis of atherosclerosis. Improvement in post-prandial hyperglycemia on alpha-glucosidase inhibitors (alpha-GIs) is associated with a risk reduction of cardiovascular diseases, but the post-prandial effects of alpha-GIs on endothelial function and incretin secretion in type 2 diabetic patients with coronary artery disease (CAD) remain unclear. METHODS AND RESULTS: The post-prandial effects of a single administration of miglitol and voglibose on endothelial function and changing levels of glucose, insulin, lipids, glucagon-like peptide (GLP)-1, and gastric inhibitory polypeptide (GIP) were compared after a standard meal loading in 11 diabetic patients with CAD, using a placebo-controlled cross-over design. The changing levels of glucose, insulin and triglycerides at 60 min were significantly lower in the miglitol group than in the voglibose and placebo groups (all P<0.01). GLP-1 levels were significantly higher at 120 min (P<0.05) and GIP levels were significantly lower at 30 min and 60 min (P<0.05) in the miglitol group compared to other treatments. The reactive hyperemia duration at 120 min was significantly maintained in the miglitol group compared to the other groups. CONCLUSIONS: A single administration of miglitol significantly improved post-prandial glucose/lipid metabolism, incretin secretion, and endothelial dysfunction in diabetic patients with CAD, suggesting that miglitol may be a useful anti-atherogenic agent (UMIN000002264). |
| | |
Authors:
|
Makoto Hiki; Kazunori Shimada; Takashi Kiyanagi; Kosuke Fukao; Kuniaki Hirose; Hiromichi Ohsaka; Yoshifumi Fukushima; Atsumi Kume; Rie Matsumori; Katsuhiko Sumiyoshi; Tetsuro Miyazaki; Hirotoshi Ohmura; Takeshi Kurata; Takashi Miida; Hiroyuki Daida |
Related Documents
:
|
15212985 - The major glucagon-like peptide-1 metabolite, glp-1-(9-36)-amide, does not affect gluco... 10983625 - Potentiation of the insulinotropic action of glp-1 by succinic acid dimethyl ester in f... 17217635 - Glp-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obe... 10194525 - The influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concent... 16006275 - Relationship between hyperglycemia and infection in critically ill patients. 23675775 - Reversal of lipotoxic effects on the insulin promoter by alverine and benfluorex: ident... |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-01 |
Journal Detail:
|
Title: Circulation journal : official journal of the Japanese Circulation Society Volume: 74 ISSN: 1347-4820 ISO Abbreviation: Circ. J. Publication Date: 2010 Jul |
Date Detail:
|
Created Date: 2010-06-30 Completed Date: 2010-10-19 Revised Date: 2011-02-18 |
Medline Journal Info:
|
Nlm Unique ID: 101137683 Medline TA: Circ J Country: Japan |
Other Details:
|
Languages: eng Pagination: 1471-8 Citation Subset: IM |
Affiliation:
|
Department of Cardiovascular Medicine, Juntendo University School of Medicine, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
1-Deoxynojirimycin
/
administration & dosage,
analogs & derivatives* Aged Coronary Artery Disease / drug therapy, etiology Coronary Disease / drug therapy*, etiology Cross-Over Studies Diabetes Mellitus, Type 2 / complications*, drug therapy Double-Blind Method Endothelium, Vascular / drug effects*, physiopathology Enzyme Inhibitors / administration & dosage Female Glucose / metabolism Humans Hypoglycemic Agents / therapeutic use Incretins / secretion* Inositol / administration & dosage, analogs & derivatives Lipid Metabolism Male Middle Aged Treatment Outcome alpha-Glucosidases / antagonists & inhibitors* |
| Chemical | |
Reg. No./Substance:
|
0/Enzyme Inhibitors; 0/Hypoglycemic Agents; 0/Incretins; 19130-96-2/1-Deoxynojirimycin; 50-99-7/Glucose; 6917-35-7/Inositol; 72432-03-2/miglitol; 83480-29-9/voglibose; EC 3.2.1.20/alpha-Glucosidases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reproducibility of high-sensitivity C-reactive protein as an inflammatory component of metabolic syn...
Next Document: Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.